Recruiting PHASE3 INTERVENTIONAL 2-arm NCT04969731

Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

An Open-label, Randomized, Multi-center, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Immuncell-LC Therapy Combined With Gemcitabine Versus Adjuvant Gemcitabine Single Therapy After Resection in Patients With Pancreatic Ductal Adenocarcinoma

Sponsor: GC Cell Corporation

Conditions Pancreatic Ductal Adenocarcinoma

Interventions Gemcitabine Immuncell-LC

Updated 6 times since 2021 Last updated: Nov 18, 2021 Started: Sep 7, 2021 Primary completion: Dec 31, 2026 Completion: Jun 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Pancreatic Ductal Adenocarcinoma and is currently actively recruiting participants. GC Cell Corporation leads this study, which shows 6 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE3
Sep 2024 — Sep 2025 [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Dec 2021 — Jul 2024 [monthly]

Recruiting PHASE3
Oct 2021 — Dec 2021 [monthly]

Recruiting PHASE3

▶ Show 1 earlier version

Sep 2021 — Oct 2021 [monthly]

Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GC Cell Corporation

Data source: GC Cell Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea